Among immune markers under investigation, interleukin-8 (IL-8) has emerged as a candidate due to its links with neuroinflammatory processes, treatment response, and potential for individualized risk profiling, particularly in treatment-resistant depression (TRD). Here, CXCL8 is linked to depressive disorder.